Immunic, inc. to participate in scientific, industry and investor conferences in july

New york, june 28, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in july: june 30-july 3: the international federation of psoriasis association's 6th world psoriasis & psoriatic arthritis conference 2021. dr. thomas m polasek, clinical pharmacology registrar, royal adelaide hospital, australia, will present the first clinical experience with imu-935, an orally available, selective inverse agonist of rorΓt.
IMUX Ratings Summary
IMUX Quant Ranking